Opioids Collections

Purdue Pharma House Oversight Committee Investigation Collection



The documents in this collection were obtained by the House Oversight Committee in connection with its investigation into the role of Purdue Pharma and the Sackler family in the opioid epidemic. The House Oversight Committee publicly released a batch of the documents on its website in October 2020, prior to a December 2020 Congressional hearing and testimony by Purdue representatives. Additional batches were released in March and April of 2021. The collection also contains the transcript of the Congressional hearing.


The collection consists of 562 documents produced by Purdue and one 70-page transcript from the December 2020 hearing. The documents consist primarily of Purdue emails and sales data. Most of the sales data relates to the drug OxyContin, but other reports discuss the drugs Butrans, Intermezzo, and Hysingla. Many of the emails involve Purdue executives and Board members, including members of the Sackler family.

Also included are reports to the Purdue Board of Directors, Compensation Committee reports, compliance reports, as well as reports and presentations from consulting firm McKinsey & Company.

The hearing transcript documents the testimony of Purdue representatives David Sackler, Kathe Sackler, and CEO Craig Landau. The witnesses were questioned about Purdue sales practices, specifically related to OxyContin, as well as large cash withdrawals from the company made by Sackler family members.

Date Range: 2008-2020

Where to Start

Access Purdue HOC Investigation at a Glance in our Research Tools area for an overview of the documents.

Related Resources